ADMA Biologics (NASDAQ:ADMA) Director Sells $139,200.00 in Stock

Key Points

  • Director Lawrence Guiheen sold 10,000 ADMA Biologics shares for $139,200 at an average price of $13.92, reducing his stake by 13.59% to 63,599 shares.
  • ADMA reported quarterly EPS of $0.23, topping the $0.20 consensus estimate, while revenue of $141.1 million also exceeded estimates and grew 5.1% year over year.
  • Analysts’ consensus rating is “Moderate Buy,” with an average price target of $17.50; three analysts rate the stock Buy and three rate it Hold.

ADMA Biologics Inc (NASDAQ:ADMA - Get Free Report) Director Lawrence Guiheen sold 10,000 shares of the company's stock in a transaction on Monday, November 16th. The shares were sold at an average price of $13.92, for a total value of $139,200.00. Following the sale, the director owned 63,599 shares of the company's stock, valued at approximately $885,298.08. The trade was a 13.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

ADMA Biologics Stock Performance

ADMA opened at $13.46 on Tuesday. The firm has a market cap of $2.99 billion, a P/E ratio of 17.48 and a beta of 0.65. ADMA Biologics Inc has a 52-week low of $7.21 and a 52-week high of $20.46. The company has a debt-to-equity ratio of 0.45, a quick ratio of 3.25 and a current ratio of 6.04. The business's fifty day moving average is $10.65 and its 200-day moving average is $10.77.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its earnings results on Wednesday, November 4th. The biotechnology company reported $0.23 EPS for the quarter, beating the consensus estimate of $0.20 by $0.03. ADMA Biologics had a net margin of 35.14% and a return on equity of 42.56%. The firm had revenue of $141.10 million for the quarter, compared to analyst estimates of $138.11 million. During the same period last year, the firm earned $0.15 EPS. The business's quarterly revenue was up 5.1% compared to the same quarter last year. Sell-side analysts expect that ADMA Biologics Inc will post 0.82 EPS for the current fiscal year.

Institutional Inflows and Outflows




Several hedge funds have recently added to or reduced their stakes in the company. NorthCrest Asset Manangement LLC lifted its position in shares of ADMA Biologics by 8.4% in the 3rd quarter. NorthCrest Asset Manangement LLC now owns 15,952 shares of the biotechnology company's stock worth $165,000 after purchasing an additional 1,234 shares during the period. Allspring Global Investments Holdings LLC boosted its stake in shares of ADMA Biologics by 4.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 32,087 shares of the biotechnology company's stock valued at $319,000 after purchasing an additional 1,316 shares during the last quarter. Pinnacle Wealth Planning Services Inc. boosted its stake in shares of ADMA Biologics by 33.1% in the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 5,721 shares of the biotechnology company's stock valued at $57,000 after purchasing an additional 1,422 shares during the last quarter. CenterBook Partners LP boosted its stake in shares of ADMA Biologics by 1.8% in the 3rd quarter. CenterBook Partners LP now owns 81,607 shares of the biotechnology company's stock valued at $819,000 after purchasing an additional 1,432 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of ADMA Biologics by 0.4% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 395,356 shares of the biotechnology company's stock worth $3,309,000 after buying an additional 1,705 shares during the period. Institutional investors own 75.68% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. Mizuho set a $18.00 price objective on shares of ADMA Biologics in a research note on Thursday, November 5th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of ADMA Biologics in a research report on Monday, September 14th. Zacks Research raised ADMA Biologics from a "strong sell" rating to a "hold" rating in a report on Wednesday, September 2nd. Finally, Cantor Fitzgerald lifted their target price on ADMA Biologics from $12.00 to $13.00 and gave the stock a "neutral" rating in a report on Thursday, November 5th. Three investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $17.50.

Read Our Latest Report on ADMA Biologics

ADMA Biologics Company Profile

(Get Free Report)

ADMA Biologics is a biopharmaceutical company that develops, manufactures and markets plasma-derived therapies for people with immune deficiencies and certain infectious diseases. Its products include BIVIGAM and ASCENIV, intravenous immune globulin therapies used to treat primary humoral immunodeficiency, and Nabi-HB, an immune globulin used for hepatitis B prevention in specific clinical settings. The company collects human plasma through its U.S. donor centers and processes it into therapies at its manufacturing facility in Boca Raton, Florida.

Further Reading

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].

Insider Buying or Selling at ADMA Biologics?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for ADMA Biologics and related companies.
Free Insider Buying and Selling Newsletter
Enter your email address below to receive InsiderTrades.com's daily insider buying and selling report.
From Our Partners

Most Read This Month

Recent Articles